Adeona Pharmaceuticals, Inc. (AEN), a development-stage, specialty pharmaceutical company, has dedicated its efforts to developing proprietary, late-stage drug candidates designed to treat autoimmune and central nervous system (CNS) diseases. The company’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have proven clinical efficacy for the treatment medical diseases that are as of yet unattended to. For further information, visit the Company’s web site at www.adeonapharma.com.
- 18 years ago
QualityStocks
Adeona Pharmaceuticals, Inc. AEN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…